Figure 1. Number of evaluable patients with acute myeloid leukemia included in the (a) 2012 cohort and the (b) 2010 cohort. CR: complete morphological remission; HSCT: hematopoietic stem cell transplantation.
| Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
| Journal website http://www.thejh.org |
Original Article
Volume 5, Number 1, March 2016, pages 1-7
Evaluation of an Outpatient Model for Treatment of Acute Myeloid Leukemia
Figure
Tables
| 2012 cohort (n = 18) | 2010 cohort (n = 11) | |
|---|---|---|
| aBaseline median platelet count at diagnosis was significantly different between groups (P = 0.028). bOne patient in 2012 cohort with t(8;21) had mutated c-KIT. | ||
| Median age (range) | 55 (24 - 67) | 59 (49 - 71) |
| Male, n | 6 | 5 |
| De Novo AML, n | 16 | 10 |
| Median blood counts at diagnosis (range) | ||
| Hemoglobin (g/L) | 89 (64 - 118) | 99 (65 - 127) |
| WBC (109/L) | 5.2 (0.8 - 89.9) | 7.7 (1.1 - 67.7) |
| ANC (109/L) | 0.8 (0.08 - 14.6) | 0.4 (0 - 10.2) |
| PLT (109/L) | 42 (10 - 183)a | 101 (15 - 307)a |
| Recurrent cytogenetics, n | ||
| t(15;17) | 3 | 2 |
| t(8;21) | 2b | 0 |
| inv(16) | 0 | 1 |
| Cytogenetics unavailable, n | 3 | 4 |
| Normal cytogenetics, n | 5 | 2 |
| WT NPM1/FLT3-ITD | 3 | 0 |
| Mutated NPM1, WT FLT3-ITD | 2 | 0 |
| WT NPM1, Mutated FLT3-ITD | 0 | 0 |
| Mutated NPM1/FLT3-ITD | 0 | 0 |
| Molecular studies unavailable | 0 | 2 |
| Risk category, n | ||
| Favorable | 6 | 3 |
| Intermediate | 6 | 4 |
| Adverse | 4 | 1 |
| Not assessable | 2 | 3 |
| Induction regimen, n | ||
| Standard “3+7” | 18 | 11 |
| Re-induction, n | ||
| MEC | 1 | 0 |
| NOVE | 0 | 1 |
| Consolidation regimen, n | ||
| HiDAC | 3 | 2 |
| ID-ARAC | 11 | 7 |
| DN-ARAC | 3 | 1 |
| MEC | 1 | 0 |
| NOVE | 0 | 1 |
| 2012 cohort, median (range) | 2010 cohort, median (range) | P | |
|---|---|---|---|
| Total number of days observed in program | 26.5 (20 - 108) | 25 (17 - 29) | 0.331 |
| Number of days as outpatient | 15.5 (0 - 27) | 0 (0 - 10) | 0.002 |
| Number of days as inpatient | 12.5 (0 - 101) | 24 (7 - 29) | 0.04 |
| Total number of days neutropenic | 16 (11 - 55) | 14 (12 - 28) | 0.735 |
| Days neutropenic as outpatient | 7 (0 - 21) | 0 (0 - 10) | 0.024 |
| Total number of days febrile | 1 (0 - 24) | 1 (0 - 7) | 0.542 |
| Number of units of PRBC transfused | 2 (1 - 12) | 2 (1 - 7) | 0.838 |
| Number of platelet pools transfused | 0 (0 - 5) | 0 (0 - 2) | 0.594 |
| Blood counts at discharge | |||
| Hemoglobin (g/L) | 103 (84 - 118) | 93 (82 - 123) | 0.137 |
| WBC (109/L) | 2.5 (1.0 - 9.3) | 2.2 (1.1 - 4.9) | 0.669 |
| ANC (109/L) | 0.8 (0.5 - 5.77) | 0.8 (0.5 - 1.37) | 0.472 |
| PLT (109/L) | 67 (10 - 398) | 77 (32 - 653) | 0.368 |